|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein-protein interaction (PPI) analysis revealed SERPINA3 and BDNF to possess high node degree interaction with literature derived candidate genes (LDGs) in AD males and females, respectively, thus were selected as potential AD targets.
|
31543038 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Statistically significant reductions in self-reported environmental asthma triggers and health improvements were found in the following areas: doctor visits, use of antibiotics for chest problems, respiratory symptoms and quality of life indicators, and asthma control (ACT score).
|
30831256 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over half (55.7%) had uncontrolled asthma as measured by ACT/cACT; 13.9% had a normal ACT/cACT score but were uncontrolled using the Asthma Control Questionnaire and 20.2% were controlled on both measures but had received oral steroids in the past year for asthma.
|
30772471 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the contrary, gender, FEV<sub>1</sub>, FEV<sub>1</sub>/FVC ratio, FEF<sub>25-75</sub>, ACT, VAS of breathing perception, oral corticosteroid use, and asthma severity grade were associated with the asthma control grade.
|
31047107 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
C-reactive protein (HR = 1.37 [1.05; 1.78]), interleukin-6 (HR = 1.40 [1.13; 1.73]), α1-antichymotrypsin (HR = 1.54 [1.14; 2.80]), lipoprotein-associated phospholipase A2 activity (HR = 1.40 [1.03; 1.90]), and fibrinogen were each associated with all-cause dementia, but neither was significantly associated with AD.
|
29605221 |
2018 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Validity indicators were calculated at different C-ACT cut-points to determine those most appropriate for predicting controlled and uncontrolled asthma.
|
29223149 |
2018 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among women who completed the ACT during the clinical interview, the 50% of women who experienced worsening asthma during pregnancy (6/12) had an ACT score below 20.
|
29692816 |
2018 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Asthma control was assessed per the 2012 GINA guidelines and the ACT questionnaire.
|
29724395 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated peripheral interleukin (IL)-1β, IL-2, IL-6, IL-18, interferon-γ, homocysteine, high-sensitivity C reactive protein, C-X-C motif chemokine-10, epidermal growth factor, vascular cell adhesion molecule-1, tumour necrosis factor (TNF)-α converting enzyme, soluble TNF receptors 1 and 2, α1-antichymotrypsin and decreased IL-1 receptor antagonist and leptin were found in patients with AD compared with HC.
|
28794151 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In FP/FORM-treated patients aged ≥12 years, asthma control (Asthma Control Test™ [ACT]), incidence of severe exacerbations, lung function, quality of life (asthma quality of life questionnaire [AQLQ]) and adverse events (AEs) were assessed over one year.
|
28947024 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No significant correlations were observed between FeNO levels and other parameters (Asthma Control Test [ACT] score or forced expiratory volume in one second [FEV<sub>1</sub>]) in mean and percentage change of values under treatment of asthma; however, significant positive correlations were found between ACT scores and FEV<sub>1</sub>.
|
29110960 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-ACT can be validity used to monitor asthma control.
|
28984253 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Measurements included fraction of exhaled nitric oxide (FENO, ppb), dynamic and static lung function, and bronchial provocation with methacholine (PD:20) and mannitol (PD:15), as well as an evaluation of respiratory symptoms using the asthma control test (C-ACT).
|
28636794 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The percentages of children showing controlled asthma (C-ACT) were 18% (pre-treatment), 69% (post-treatment), and 44% (follow-up).
|
27736038 |
2017 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency of VDR ApaI aa genotype was significantly higher in controlled asthma group (n=92) than uncontrolled asthma group (n=35), according to C-ACT (24.5% vs 0.0%, p<0.001) and GINA (32.7% vs 7.5%, p=0.001).
|
25353337 |
2014 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, ACT-17 variation presents a risk factor for AD in the worldwide population, especially in the Caucasian population.
|
22272609 |
2013 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modest evidence for association with asthma was observed for 2 CNVs near NOS1 and SERPINA3.
|
23517041 |
2013 |
|
Low density lipoprotein cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Serum LDL cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, whether the genetic variants in the regulatory region (including the promoter and the two enhancers) of the ACT gene affect susceptibility to Alzheimer's disease (AD) remains controversial.
|
20378355 |
2010 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have investigated whether the -86 C/T promoter polymorphism in CHRNA7 gene, the signal peptide polymorphism of the alpha1-antichymotripsin (ACT) gene or the APOE genotype are associated with an increased risk of mild cognitive impairment (MCI) or affect the risk of evolution to Alzheimer's disease (AD).
|
18078695 |
2009 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACT levels were higher in AD patients than in CIND or controls.
|
18991685 |
2008 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher CSF levels of neuroserpin and alpha(1)-antichymotrypsin were associated with the clinical diagnosis of Alzheimer disease (AD) and facilitated the diagnostic classification of AD vs controls.
|
17761554 |
2007 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This result was further confirmed by the finding that addition of purified ACT induced the same Alzheimer's disease-related tau hyperphosphorylation in cortical neurons cultured in vitro.
|
16987932 |
2006 |